InspireMD announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course 2024, which is being held May 28-31, in Leipzig, Germany. Marvin Slosman, chief executive officer of InspireMD, stated, “At last year’s VIVA and VEITH conferences in November, Dr. Metzger, principal investigator for the C-GUARDIANS trial, presented positive 30-day follow-up data from the trial which demonstrated a DSMI1 rate of just 0.95% in the Intent-To-Treat analysis population, and 0.63% in the per-protocol analysis population. We are very excited to announce today that an abstract of the 12-month outcomes data from this important trial has been accepted for presentation at the upcoming LINC 2024 conference, which is among the most influential and widely attended meetings focused on vascular intervention.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSPR:
- InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- InspireMD reports Q4 EPS (16c) vs (60c) last year
- NSPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuardâ„¢ Neuroprotection System
- InspireMD appoints principal investigators for C-GUARDIANS II clinical trial